Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Consensus Rating of “Hold” from Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has received an average rating of “Hold” from the five research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $8.00.

A number of equities research analysts have issued reports on the company. Wall Street Zen upgraded Sensus Healthcare from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 22nd.

Insiders Place Their Bets

In related news, CEO Joseph C. Sardano purchased 25,000 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was acquired at an average price of $4.03 per share, with a total value of $100,750.00. Following the completion of the acquisition, the chief executive officer owned 1,200,293 shares of the company’s stock, valued at approximately $4,837,180.79. This trade represents a 2.13% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Eric Sachetta purchased 7,000 shares of Sensus Healthcare stock in a transaction on Friday, November 21st. The stock was bought at an average price of $3.93 per share, with a total value of $27,510.00. Following the transaction, the director owned 140,113 shares of the company’s stock, valued at approximately $550,644.09. This represents a 5.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 36,500 shares of company stock valued at $147,570. Insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Vise Technologies Inc. purchased a new stake in Sensus Healthcare in the 2nd quarter worth approximately $52,000. Opes Wealth Management LLC purchased a new position in Sensus Healthcare during the third quarter valued at approximately $50,000. Chapin Davis Inc. boosted its position in shares of Sensus Healthcare by 66.7% in the second quarter. Chapin Davis Inc. now owns 25,000 shares of the company’s stock worth $118,000 after purchasing an additional 10,000 shares during the period. Mindset Wealth Management LLC increased its stake in shares of Sensus Healthcare by 28.1% in the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Evernest Financial Advisors LLC bought a new stake in shares of Sensus Healthcare during the 2nd quarter valued at $255,000. 25.30% of the stock is currently owned by institutional investors.

Sensus Healthcare Price Performance

NASDAQ SRTS opened at $5.30 on Friday. The stock has a market capitalization of $87.05 million, a price-to-earnings ratio of -27.89 and a beta of 1.21. Sensus Healthcare has a 1-year low of $3.03 and a 1-year high of $9.08. The business’s fifty day moving average price is $4.14 and its 200-day moving average price is $3.89.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.06. Sensus Healthcare had a negative return on equity of 5.67% and a negative net margin of 8.44%.The company had revenue of $6.88 million during the quarter, compared to analyst estimates of $6.31 million. Equities research analysts anticipate that Sensus Healthcare will post 0.32 EPS for the current year.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.